These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17064068)

  • 1. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
    J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
    Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
    Wyatt PG; Woodhead AJ; Berdini V; Boulstridge JA; Carr MG; Cross DM; Davis DJ; Devine LA; Early TR; Feltell RE; Lewis EJ; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Reule M; Saxty G; Seavers LC; Smith DM; Squires MS; Trewartha G; Walker MT; Woolford AJ
    J Med Chem; 2008 Aug; 51(16):4986-99. PubMed ID: 18656911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
    J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
    Jorda R; Schütznerová E; Cankař P; Brychtová V; Navrátilová J; Kryštof V
    Bioorg Med Chem; 2015 May; 23(9):1975-81. PubMed ID: 25835357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
    Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
    J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
    J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
    Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
    J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzodipyrazoles: a new class of potent CDK2 inhibitors.
    D'Alessio R; Bargiotti A; Metz S; Brasca MG; Cameron A; Ermoli A; Marsiglio A; Polucci P; Roletto F; Tibolla M; Vazquez ML; Vulpetti A; Pevarello P
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1315-9. PubMed ID: 15713378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
    Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
    Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
    Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
    Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
    Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives.
    Zheng LW; Zhu J; Zhao BX; Huang YH; Ding J; Miao JY
    Eur J Med Chem; 2010 Dec; 45(12):5792-9. PubMed ID: 20947221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
    Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
    J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.